• 6767 Bertner Ave, Mitchell Basic Science Research Building

    77030 Houston

    United States

  • 38020 Citations
  • 100 h-Index
1991 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 30 Similar Profiles
Myelodysplastic Syndromes Medicine & Life Sciences
Acute Myeloid Leukemia Medicine & Life Sciences
decitabine Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Precursor Cell Lymphoblastic Leukemia-Lymphoma Medicine & Life Sciences
Survival Medicine & Life Sciences
Leukemia Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1991 2019

1 Citation (Scopus)

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Savona, M. R., Odenike, O., Amrein, P. C., Steensma, D. P., DeZern, A. E., Michaelis, L. C., Faderl, S., Harb, W., Kantarjian, H. M., Lowder, J., Oganesian, A., Azab, M. & Garcia-Manero, G., Apr 1 2019, In : The Lancet Haematology. 6, 4, p. e194-e203

Research output: Contribution to journalArticle

decitabine
Myelodysplastic Syndromes
Area Under Curve
Cytidine Deaminase
Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Diploidy
Cytogenetics
Survival

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial

Garcia-Manero, G., Almeida, A., Fenaux, P., Gattermann, N., Giagounidis, A., Goldberg, S. L., Ozawa, K., Weaver, J. & Santini, V., Apr 1 2019, In : Clinical Lymphoma, Myeloma and Leukemia. 19, 4, p. 213-219.e4

Research output: Contribution to journalArticle

Myelodysplastic Syndromes
Erythrocyte Transfusion
Placebos
Therapeutics
lenalidomide

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

Zhang, H., Savage, S., Schultz, A. R., Bottomly, D., White, L., Segerdell, E., Wilmot, B., McWeeney, S. K., Eide, C. A., Nechiporuk, T., Carlos, A., Henson, R., Lin, C., Searles, R., Ho, H., Lam, Y. L., Sweat, R., Follit, C., Jain, V., Lind, E. & 10 othersBorthakur, G., Garcia-Manero, G., Ravandi-Kashani, F., Kantarjian, H. M., Cortes, J. E., Collins, R., Buelow, D. R., Baker, S. D., Druker, B. J. & Tyner, J. W., Dec 1 2019, In : Nature communications. 10, 1, 244.

Research output: Contribution to journalArticle

Open Access
leukemias
mutations
Acute Myeloid Leukemia
Mutation
inhibitors
Myelodysplastic Syndromes
Hematopoiesis
Comorbidity
Mutation
Janus Kinase 2